2. Academic Validation
  3. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model

Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model

  • Virus Res. 2017 Jan 15;228:7-13. doi: 10.1016/j.virusres.2016.11.011.
Adriaan H de Wilde 1,  Darryl Falzarano 2,  Jessika C Zevenhoven-Dobbe 3,  Corrine Beugeling 3,  Craig Fett 4,  Cynthia Martellaro 2,  Clara C Posthuma 3,  Heinz Feldmann 2,  Stanley Perlman 4,  Eric J Snijder 5
Affiliations

Affiliations

  • 1 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: [email protected].
  • 2 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, USA.
  • 3 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
  • 4 Department of Microbiology, University of Iowa, Iowa City, USA.
  • 5 Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: [email protected].
PMID: 27840112 DOI: 10.1016/j.virusres.2016.11.011
Abstract

Currently, there is no registered treatment for infections with emerging zoonotic coronaviruses like SARS- and MERS-coronavirus. We here report that in cultured cells low-micromolar concentrations of alisporivir, a non-immunosuppressive cyclosporin A-analog, inhibit the replication of four different coronaviruses, including MERS- and SARS-coronavirus. Ribavirin was found to further potentiate the Antiviral effect of alisporivir in these cell culture-based Infection models, but this combination treatment was unable to improve the outcome of SARS-CoV Infection in a mouse model. Nevertheless, our data provide a basis to further explore the potential of Cyp inhibitors as host-directed, broad-spectrum inhibitors of coronavirus replication.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12559
    98.85%, Cyclophilin Inhibitor
    HCV